IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 118 filers reported holding IMMUNOVANT INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,011,146 | +207.2% | 964,083 | +51.8% | 0.43% | +203.5% |
| Q2 2023 | $12,047,676 | +464.5% | 635,091 | +361.6% | 0.14% | +393.1% |
| Q1 2023 | $2,134,052 | -85.3% | 137,592 | -83.2% | 0.03% | -85.1% |
| Q4 2022 | $14,501,022 | +47.3% | 816,959 | -53.7% | 0.19% | +40.6% |
| Q3 2022 | $9,845,000 | +2642.3% | 1,764,290 | +1815.6% | 0.14% | +2200.0% |
| Q2 2022 | $359,000 | -82.9% | 92,100 | -61.9% | 0.01% | -82.4% |
| Q3 2021 | $2,099,000 | -94.7% | 241,599 | -93.6% | 0.03% | -95.4% |
| Q2 2021 | $39,644,000 | +175.7% | 3,750,575 | +318.3% | 0.74% | +131.7% |
| Q1 2021 | $14,382,000 | +3.1% | 896,617 | +197.0% | 0.32% | -13.8% |
| Q4 2020 | $13,945,000 | +180.7% | 301,903 | +113.9% | 0.37% | +127.0% |
| Q3 2020 | $4,968,000 | -11.6% | 141,170 | -38.9% | 0.16% | -26.9% |
| Q2 2020 | $5,623,000 | +11.1% | 230,908 | -29.0% | 0.22% | -38.4% |
| Q1 2020 | $5,061,000 | +17.2% | 325,183 | +19.3% | 0.36% | +104.5% |
| Q4 2019 | $4,320,000 | – | 272,539 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |